AstraZeneca says detained China head has lawyer

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, ...
Trump has threatened to slap a tariff of up to 60% on all goods imported to the U.S. from China. But Soriot called his ...